How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/ebstein-s-anomaly-of-tricuspid-valve.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ebstein's anomaly of tricuspid valve — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ebstein's anomaly of tricuspid valve (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Ebstein's anomaly of tricuspid valve, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Caverject	ALPROSTADIL	Pfizer	Prostaglandin Analog [EPC]	Prostaglandin E2 receptor EP3 subtype		1981-01-01
Prostavasin	Prostavasin	Hannover Medical School		Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Hannover Medical School · 1 drug in Ebstein's anomaly of tricuspid valve
Pfizer · 1 drug in Ebstein's anomaly of tricuspid valve

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Ebstein's anomaly of tricuspid valve:

Cite this brief

Drug Landscape (2026). Ebstein's anomaly of tricuspid valve — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/ebstein-s-anomaly-of-tricuspid-valve. Accessed 2026-06-10.

Ebstein's anomaly of tricuspid valve full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing